STUDY OF BIOEQUIVALENCE OF MAGNESIUM AND SODIUM VALPROATES
STUDY OF BIOEQUIVALENCE OF MAGNESIUM AND SODIUM VALPROATES
复制标题
DOI：
10.1016/0731-7085(91)80200-s
复制
发表时间：
1991-01-01
影响因子：
3.4
通讯作者：
SANNITA, WG
中科院分区：
文献类型：
--
作者：
BALBI, A;SOTTOFATTORI, E;SANNITA, WG
已将丙戊酸镁（500和1000 mg）肠溶片的体内生物利用度与丙戊酸钠（Depakine（R））（500和1000 mg）肠溶片进行了比较。发现两种制剂具有生物等效性;与丙戊酸钠相比，丙戊酸镁似乎是一种没有生物利用度问题的药物，受试者间变异性降低。描述了测定丙戊酸盐的反相HPLC法。
The in vivo bioavailability of magnesium valproate (500 and 1000 mg) enteric-coated tablets has been compared with that of sodium valproate (Depakine(R)) (500 and 1000 mg) enteric-coated tablets. The two preparations were found to be bioequivalent; magnesium valproate appeared to be a drug without bioavailability problems and with reduced intersubject variability, compared with that of sodium valproate. A reversed-phase HPLC method for the determination of valproates is described.